Revusiran (ALN-TTRSC) + Sterile Normal Saline (0.9% NaCl)
Phase 3CompletedDevelopment Stage
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related, Familial Transthyretin Cardiac Amyloidosis
Dec 1, 2014 → Mar 30, 2017
About Revusiran (ALN-TTRSC) + Sterile Normal Saline (0.9% NaCl)
Revusiran (ALN-TTRSC) + Sterile Normal Saline (0.9% NaCl) is a phase 3 stage product being developed by Alnylam Pharmaceuticals for Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC). The current trial status is completed. This product is registered under clinical trial identifier NCT02319005. Target conditions include Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02319005 | Phase 3 | Completed |
Competing Products
20 competing products in Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 33 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | AstraZeneca | Pre-clinical | 23 |
| Eplontersen | AstraZeneca | Phase 3 | 77 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 3 | 76 |
| NNC6019-0001 | Novo Nordisk | Phase 2 | 51 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 2 | 51 |
| Coramitug | Novo Nordisk | Phase 1 | 32 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| tafamidis meglumine | Pfizer | Approved | 84 |
| Fx-1006A | Pfizer | Phase 2 | 51 |
| Tafamidis | Pfizer | Phase 3 | 76 |
| Tafamidis 61 milligrams | Pfizer | Pre-clinical | 22 |
| Treatment for TTR amyloidosis + Treatment for TTR amyloidosis | Pfizer | Pre-clinical | 22 |
| Vyndaqel | Pfizer | Pre-clinical | 22 |
| tafamidis | Pfizer | Phase 3 | 76 |
| Tafamidis | Pfizer | Approved | 84 |
| Tafamidis | Pfizer | Pre-clinical | 22 |